ライフサイエンスコーパス: renal failure

1 y, one had hepatorenal syndrome, and one had renal failure).

2 age, 34.1% on anticoagulants, and 14.7% with renal failure.

3 crescentic glomerulonephritis, and end-stage renal failure.

4 ANCA-associated GN is a significant cause of renal failure.

5 eath associated with massive albuminuria and renal failure.

6 loss phenotype of KO mice, independent from renal failure.

7 and in the kidney, it predicts the onset of renal failure.

8 a common cause of childhood hypertension and renal failure.

9 limited, but suggested an increased risk of renal failure.

10 loop that regulates FGF23 expression during renal failure.

11 of diabetes mellitus and possibly of chronic renal failure.

12 uld be dedicated to preventing postoperative renal failure.

13 he kidney and, in some cases, progression to renal failure.

14 s crucial for inducing FGF23 production upon renal failure.

15 essive tubulointerstitial fibrosis (TIF) and renal failure.

16 that requires several months to progress to renal failure.

17 to prolonged survival albeit frequently with renal failure.

18 osis (dRTA) may lead to nephrocalcinosis and renal failure.

19 ADPKD) is the most frequent genetic cause of renal failure.

20 ect that leads to progressive juvenile-onset renal failure.

21 s essential for the progression to end-stage renal failure.

22 ute kidney injury that can lead to end-stage renal failure.

23 cystic kidney disease (ADPKD) and ultimately renal failure.

24 long bones regulates FGF23 production during renal failure.

25 thrombotic microangiopathy (TMA) that causes renal failure.

26 ditary disorder characterized by progressive renal failure.

27 and decreasing proportion of respiratory and renal failure.

28 t frequently causes ureteral obstruction and renal failure.

29 SHPT is a frequent consequence of chronic renal failure.

30 , damage to the glycocalyx, proteinuria, and renal failure.

31 r cardiovascular disease events, stroke, and renal failure.

32 y is an important cause of acute and chronic renal failure.

33 cytes may be a therapeutic target in chronic renal failure.

34 quently, the G3YR adult mice suffered severe renal failure.

35 onic kidney disease progression to end-stage renal failure.

36 nib group died from drug-related hepatic and renal failure.

37 tokine TNF are likely to provoke episodes of renal failure.

38 were normal, but she had rapidly progressive renal failure.

39 optimum form of vascular access in end-stage renal failure.

40 thic hemolytic anemia, thrombocytopenia, and renal failure.

41 re phenotype showing progressive hepatic and renal failure.

42 etween ages 2.7 and 28 years, typically from renal failure.

43 ; the most common of these effects was acute renal failure.

44 ation is the optimum treatment for end-stage renal failure.

45 ses the risk for developing hypertension and renal failure.

46 linical problem that can result in end-stage renal failure.

47 neumonia, peritonitis, severe arrhythmia, or renal failure.

48 tinopathy, new or worsening albuminuria, and renal failure.

49 ovarian failure, chronic liver disease, and renal failure.

50 diabetes and the leading cause of end-stage renal failure.

51 ive GN and 15,614 individuals with nonimmune renal failure.

52 ctions are leading causes of pediatric acute renal failure.

53 abetic nephropathy, leading to sclerosis and renal failure.

54 ease (ADPKD) is the leading genetic cause of renal failure.

55 st formation that, ultimately, culminates in renal failure.

56 tery disease, chronic pulmonary disease, and renal failure.

57 of hematological malignancies with end-stage renal failure.

58 by hypoxic respiratory failure and oliguric renal failure.

59 besity, type II diabetes, heart failure, and renal failure.

60 ciated nephropathy is the commonest cause of renal failure.

61 t may be useful in patients with concomitant renal failure.

62 infection, cardiovascular events, and acute renal failure.

63 is the most common genetic disorder causing renal failure.

64 versible tissue and organ damage and chronic renal failure.

65 on 2.0%, mortality 0.6%, tamponade 0.3%, and renal failure 0.2%.

66 ys included death (3.6%), stroke (2.3%), and renal failure (1.5%).

67 95% confidence interval [CI], 1.00-1.94) for renal failure, 1.34 (95% CI, 0.96-1.86) for shock durati

68 cations was wound infection (3.8%, $21,995), renal failure (2.8%, $19,201), respiratory failure (2.7%

69 d to treatment), pneumonia (27 [11%]), acute renal failure (25 [10%]; five related to treatment), pyr

70 , for stroke 26%, for heart failure 37%, for renal failure 28%, and for all-cause mortality 35%.

71 t patients were more likely to have comorbid renal failure (36% versus 24%), coronary artery disease

72 65 years (81.5%), diabetes (41.0%), moderate renal failure (40.2%), peripheral artery disease (33.7%)

73 ory support-related complications were acute renal failure 41%, bleeding 25%, neurologic damage in su

74 ost common serious adverse events were acute renal failure (41 [3.2%] vs 33 [2.5%]) and supraventricu

75 th (2.3%, 0.8%, and 0.6%; P = .02) and acute renal failure (6.2%, 7.6%, and 2.4%; P < .001) after ASA

76 1%), valvular heart disease (5.0%-9.8%), and renal failure (7.1%-19.6%; P<0.001 for all).

77 One example is acute renal failure, a major cause of morbidity and mortality

78 ed by kidney antibrush border antibodies and renal failure (ABBA disease).

79 Sex did not influence mortality and renal failure according to the different coronary revasc

80 leading to life-threatening anemia and acute renal failure across endemic areas.

81 were confirmed in two independent models of renal failure, adenine diet induced and 5/6 nephrectomy.

82 levant risk factors, including age, sex, and renal failure (adjusted hazard ratio 2.08; 95% confidenc

83 Acute renal failure (adjusted odds ratio [AOR], 3.01; 95% conf

84 5% CI: 1.23 to 1.62; p < 0.001), and chronic renal failure (aHR: 1.37; 95% CI: 1.23 to 1.53; p < 0.00

85 gest the possibility of stratifying risk for renal failure among lithium-treated patients.

86 , myocardial infarction, pneumonia, or acute renal failure and a length of stay >75th percentile).

87 and prognosis of several diseases including renal failure and cancer.

88 , a severe multisystem presentation (chronic renal failure and cardiomyopathy) in infancy.

89 (PKDs) are genetic disorders that can cause renal failure and death in children and adults.

90 ; two adverse events leading to death (acute renal failure and death, cause unknown) were possibly re

91 wer to assess clinical safety events such as renal failure and fractures, our data suggest that E/C/F

92 lso results in hyperoxaluria promoting acute renal failure and frequently death.

93 postcolonoscopy complications such as acute renal failure and GI bleeding, especially in patients wi

94 tified as independent risk factors for acute renal failure and GI bleeding.

95 .51), of which 28% was explained by comorbid renal failure and hazardous alcohol use.

96 s were strongest between ED visits for acute renal failure and heat waves defined by maximum apparent

97 The latter can lead to potentially fatal renal failure and is caused by the release of Shiga toxi

98 e entity, is known to present as progressive renal failure and its leading presentation with scrotal

99 s glomeruli and progresses towards end stage renal failure and multiple organ dysfunction.

100 ute respiratory distress syndrome, steroids, renal failure and need for vasopressors).

101 and severe long term complications, notably renal failure and neurological impairment.

102 Both donors had renal failure and pretransplant renal biopsies showing 1

103 ve AAGN patients who had developed end-stage renal failure and received a kidney allograft in 1 of 6

104 ct obstruction, hydroureter, hydronephrosis, renal failure and reduced bladder capacity.

105 The primary events were renal (incident renal failure and renal replacement therapy [RRT]) and b

106 and urinary sepsis in one patient, and acute renal failure and respiratory failure in one patient) we

107 le-treated I/R injury which exhibited severe renal failure and tubular damage at 24 hours.

108 ignificant protection from I/R-induced acute renal failure and tubular damage.

109 ospital AF relapse and comorbidities such as renal failure and valvular heart disease are independent

110 e events (myasthenia gravis and worsening of renal failure), and one patient who received nivolumab 3

111 ronary heart disease, stroke, heart failure, renal failure, and all-cause mortality.

112 Sex, renal failure, and atrial fibrillation affected mortalit

113 cells in asthma, kidney epithelial cells in renal failure, and cortical and hippocampal neurons in b

114 ng, steroid, congestive heart failure, acute renal failure, and dyspnea) were analyzed in terms of ag

115 EC) infection causes severe bloody diarrhea, renal failure, and hemolytic uremic syndrome.

116 t for diagnosis of acalculous cholecystitis, renal failure, and interstitial and parenchymal lung dis

117 Safety end points were in-hospital stroke, renal failure, and major bleeding.

118 , smoking, diabetes, liver disease, obesity, renal failure, and malnutrition showed good discriminati

119 pital events (death, stroke, bleeding, acute renal failure, and need for permanent pacemaker) were ex

120 n obvious cause, and may include fever, mild renal failure, and neurologic deficits.

121 ng congenital bilateral cataracts, glaucoma, renal failure, and neurological impairments.

122 ey fibrosis contributes greatly to end-stage renal failure, and no specific treatment is available to

123 luding myocardial infarction, heart failure, renal failure, and stroke.

124 which would put them at risk for cardiac or renal failure, and thus represented a poor-risk group.

125 ovenous extracorporeal membrane oxygenation, renal failure, and underlying malignant disease.

126 ytopenia, blood dyscrasias, hepatic disease, renal failure, antithrombotic medication, and presence o

127 ted with lower rates of BVD, whereas chronic renal failure (aOR: 1.46; 95% CI: 1.03 to 2.08; p = 0.03

128 The most prevalent complications were acute renal failure (ARF)(24.2%), septicemia (18.2%), and pneu

129 of postoperative 180-day mortality and acute renal failure (ARF), improving upon predictions that rel

130 rbidities such as valvular heart disease and renal failure as well as an early AF relapse were also p

131 Compound 8 also effectively attenuated renal failure, as measured by BUN levels in mice fed an

132 mechanisms of drug metabolism in hepatic and renal failure, as well as posttransplant drug-drug inter

133 onary hypertension to pulmonary, cardiac and renal failure, ascites and encephalopathy.

134 es or rehospitalization for heart failure or renal failure at 180 days, or the length of the index ho

135 verely debilitating for patients, leading to renal failure at young age.

136 may reduce the risk of short-term mortality, renal failure, atrial fibrillation, bleeding, and length

137 re (beta, 20 min; CI, 14-25; p < 0.001), and renal failure (beta, 16 min; CI, 10-22; p < 0.001).

138 PGF and other postoperative events, such as renal failure, biopsy-proven rejection, and stroke.

139 as associated with an increased incidence of renal failure but not with faster reversal of shock or i

140 years; P<0.001), with more hypertension and renal failure, but had less coronary disease, less previ

141 iciency was identified using the presence of renal failure by ICD9 code or laboratory-confirmed glome

142 for >=48 hours (c-statistic 0.86), and acute renal failure (c-statistic 0.85).

143 1390A > G in the Coronary Artery Disease and Renal Failure (CAD-REF) registry with a mean eGFR of 47.

144 End stage renal failure can be seen very rare.

145 itus, osteoporosis, non-AIDS cancer, chronic renal failure, cardio and cerebrovascular disease, obesi

146 itus, osteoporosis, non-AIDS cancer, chronic renal failure, cardiovascular and cerebrovascular diseas

147 analyzed included diabetes mellitus, chronic renal failure, cardiovascular events, NLR-NAR cancer, bo

148 0.024) and decline in the hazard of chronic renal failure close to the threshold of significance (sH

149 ial biopsies of DCM patients associated with renal failure compared to DCM alone.

150 hould be closely monitored for patients with renal failure, concomitant aspirin use, and poor INR con

151 cal site infection, respiratory failure, and renal failure contributed the most to annual cost burden

152 was calculated by assigning 1 point each for renal failure, coronary artery disease, diabetes mellitu

153 e of mortality, myocardial infarction, acute renal failure, coronary revascularization, or stroke wit

154 Chronic renal failure (CRF) is a major public health problem wor

155 erbilirubinemia and/or Encephalopathy and/or Renal Failure dataset with adoption of the Chronic Liver

156 Incidence of acute renal failure decreased in the PBM cohort (2.39% vs 1.67

157 te for mortality or major morbidity (stroke, renal failure, deep sternal wound infection, reoperation

158 rious infections, any infection, hemorrhage, renal failure, deep vein thrombosis, and uncontrollable

159 hemodialysis, or nondialysis who experienced renal failure developed NSF after administration of gado

160 HNF1B mutations develop progressive chronic renal failure, diabetes mellitus (40-50%), and liver tes

161 populations with chronic conditions such as renal failure, diabetes, HIV and alcohol abuse.

162 We correlated data with the degree of renal failure (dialysis or nondialysis), prior immunosup

163 a with a history of hypertension and chronic renal failure due to renal artery occlusion was treated

164 n Sequential Organ Failure Assessment score, renal failure, encephalopathy, and mechanical ventilatio

165 Acute tubular damage is a major cause of renal failure, especially at the early phase of kidney t

166 first occurrence of adjudicated death due to renal failure, ESRD, or sustained 40% or higher decrease

167 otection even in the unfavourable context of renal failure, extending the evidence for an important c

168 d to determine the cause or reversibility of renal failure for patients with end-stage liver disease

169 ts died, including 3 who had respiratory and renal failure, for a mortality of 18.5%.

170 ic nephropathy, one of the leading causes of renal failure, for which currently no treatment exists.

171 rotective background and postpones end stage renal failure from 7 weeks, as seen on a C3H background,

172 ical history was also complicated by stage 4 renal failure from long-standing type II diabetes, hyper

173 O-MRSA were more likely to have a history of renal failure, hemodialysis, residence in a long-term-ca

174 In chronic renal failure, higher circulating AGE levels result from

175 human diseases with eventual development of renal failure; however, effective treatment is lacking.

176 of upper limb ischemia - diabetes, end-stage renal failure, hyperparathyroidism, or even symptoms of

177 In renal failure, hyperphosphatemia occurs despite a marked

178 t polycystic kidney disease patients develop renal failure, hypertension, left ventricular hypertroph

179 higher rates of infusion-related reactions, renal failure, hypokalemia, hypomagnesemia, and anemia t

180 initiation time and baseline heart failure, renal failure, hypotension, acute kidney injury, altered

181 The rapidly evolving renal failure, hypotension, pressor and steroid use, and

182 Cryptosporidiosis was complicated by renal failure in 15 patients.

183 cause of death was tentatively attributed to renal failure in 37 cases, mostly on the basis of report

184 lial regeneration leads to the resolution of renal failure in AKI.

185 The cause of the renal failure in COVID-19 is unknown, but one hypothesiz

186 the most common monogenic cause of end-stage renal failure in humans and results from germline mutati

187 onium excretion is associated with death and renal failure in hypertensive kidney disease, even among

188 The role of renal failure in late deaths after recovery from Ebola v

189 Thus, we induced renal failure in mice with targeted deletion of Klotho i

190 fibrillation include patients with end-stage renal failure (including those receiving dialysis), extr

191 pment of HUS, complications (ie, oligoanuric renal failure, involvement of the central nervous system

192 Classic calciphylaxis associated with renal failure is a life-threatening disease.

193 threatening complication directly related to renal failure is a subject of debate.

194 strategies for any PH type in patients with renal failure is largely unproven.

195 Renal failure is the most significant organ dysfunction

196 eted treatment available and, in some cases, renal failure is unavoidable.

197 composite of death from any cause or severe renal failure leading to renal replacement therapy withi

198 0-day risk of a composite of death or severe renal failure leading to renal-replacement therapy was l

199 end point was a composite of death or severe renal failure leading to renal-replacement therapy withi

200 pulation, may help elucidate the etiology of renal failure, may predict post-LAT kidney function, and

201 dary outcomes included encephalopathy, acute renal failure, mechanical ventilation, and discharge hom

202 Before the onset of renal failure, mice overexpressing RFS-kappaLCs showed P

203 ave been a successful therapy in several rat renal failure models.

204 lead to venous/arterial thrombosis, stroke, renal failure, myocardial infarction, thrombocytopenia,

205 n=1), neurological decompensation (n=1), and renal failure (n=1).

206 mpared the T cell phenotype in children with renal failure (n=80) with that in healthy children (n=20

207 OR, 9.45; 95% CI, 3.41-26.18; P < .001), new renal failure necessitating dialysis (OR, 14.48; 95% CI,

208 Conclusion In the absence of known renal failure, neonates receiving standard inpatient car

209 It may contribute to the renal failure observed in nonsurviving patients.

210 nt predictors for in-hospital mortality were renal failure (odds ratio [OR], 2.6 [95% confidence inte

211 nts in the sunitinib group (one case each of renal failure, oesophageal varices haemorrhage, circulat

212 Renal failure of grade III or IV was seen in 5 patients

213 Nevertheless, patients with SAD-APS and renal failure only represent 2% to 5% in hemodialysis or

214 patient categories such as those with severe renal failure or antiphospholipid syndrome, or cancer, r

215 was consistent for others except people with renal failure or on immunosuppressants (2.1%, 95%CI -7.2

216 nce among people 1) living with HIV; 2) with renal failure or receiving immunosuppressants; 3) using

217 onary disease (OR, 1.33; 95% CI, 1.27-1.39); renal failure (OR, 1.26; 95% CI, 1.18-1.36); diabetes (O

218 ke (OR, 1.64; 95% CI, 0.98-2.72; P=0.06) and renal failure (OR, 1.30; 95% CI, 0.98-1.72; P=0.06), wit

219 embolism (OR:2.11; 95% CI: 1.70-2.61), acute renal failure (OR: 1.34; 95% CI; 1.22-1.47), and sepsis

220 llin" and "tazobactam"] and ["AKI" or "acute renal failure" or "nephrotoxicity"] and registered meta-

221 llin" and "tazobactam"] and ["AKI" or "acute renal failure" or "nephrotoxicity"] and registered meta-

222 dial infarction, stroke, pulmonary embolism, renal failure, or bowel infarction) within 30 days after

223 ctions of age, sex, ischemic cardiomyopathy, renal failure, or QRS duration were not significant.

224 had an increased risk of dialysis-dependent renal failure (P < 0.05).

225 ancy (non-Hodgkin's lymphoma, leukemia), and renal failure (P </= 0.03 for all).

226 there was a significantly increased risk for renal failure (P = 0.001) and gastrointestinal (GI) blee

227 ies except for dialysis (P = 0.07) and acute renal failure (P = 0.19).

228 ularization strategy regarding mortality and renal failure (P(interaction)=0.11).

229 ntation, but the increasing prevalence among renal failure patients has forced some centers to carefu

230 eating thyroid cancer with iodine in chronic renal failure patients who require hemodialysis and deta

231 PV=69%) but lower for bleeding (PPV=40%) and renal failure (PPV=19%).

232 Notably, acute renal failure predicted worse outcomes and performing an

233 ate that, prior to transplant, patients with renal failure present with heterogeneous levels of IgG h

234 ronic obstructive pulmonary disease, chronic renal failure, previous invasive coronary strategy, and

235 aneous remission (P=0.03) and lower rates of renal failure progression (P=0.002) and ESRD (P=0.01) du

236 in 2; postinterventional stroke, progressive renal failure, progressive heart failure, or combination

237 geons measure: deep sternal wound infection, renal failure, prolonged ventilation >24 hours, stroke,

238 ions between current smoking and deaths from renal failure (relative risk, 2.0; 95% confidence interv

239 ritis or interstitial nephritis, as cause of renal failure, represented the only predictive factor fo

240 ubsequent hospital course was complicated by renal failure requiring continuous renal replacement the

241 cardiac arrest (10%), sepsis (7%), and acute renal failure requiring dialysis (3%).

242 He developed seizures and acute renal failure requiring intubation and plasma exchange i

243 Renal failure requiring renal replacement therapy (RRT)

244 Only mechanical ventilation days and acute renal failure requiring renal replacement therapy predic

245 spiratory distress syndrome (ARDS) and acute renal failure, requiring mechanical ventilation, vasopre

246 equal to 2.5 mum (PM2.5), and mortality from renal failure (RF) among participants in the Elderly Hea

247 e events (RR: 1.02; 95% CI: 0.94 to 1.09) or renal failure (RR: 1.81; 95% CI: 0.86 to 3.80) between t

248 sults, except for an increase in the risk of renal failure (RR: 2.03; 95% CI: 1.30 to 3.18) with inte

249 ciated with failure to rescue included acute renal failure, septic shock, and postoperative pulmonary

250 use and the number of days alive and free of renal failure, shock, and death, all on day 14.

251 Factors potentially limiting use of TRI (renal failure, shock, cardiac arrest, and mechanical cir

252 d bacteremia, pulmonary complications, acute renal failure, shock, intensive care unit admission, nee

253 rmed with no conversion to midsternotomy, no renal failure, strokes, or operative mortality (<30 days

254 ent therapy) to $876,539 (data from an acute renal failure study in which continuous renal replacemen

255 The general assessment revealed a renal failure symptomatic of a nephrotic syndrome, assoc

256 ts in the LIMP-2 gene cause action myoclonus-renal failure syndrome and also have been linked to PD.

257 nt of multiple renal cysts, often leading to renal failure that cannot be prevented by a current trea

258 Diabetic kidney disease is a major cause of renal failure that urgently necessitates a breakthrough

259 In end-stage renal failure, the net clinical benefit of VKAs in dialy

260 c uraemic syndrome is a triad of progressive renal failure, thrombocytopenia and haemolytic anaemia w

261 threatening complication directly related to renal failure to either an early or a delayed strategy o

262 Exclusion criteria were acute renal failure, trauma, and surgery within 2 days.

263 erbilirubinemia and/or Encephalopathy and/or Renal Failure trial by applying the recently introduced

264 aphic data and effluent rates from the Acute Renal Failure Trial Network and RENAL Replacement Therap

265 d high-intensity treatment arms of the Acute Renal Failure Trial Network and RENAL Replacement Therap

266 The Acute Renal Failure Trial Network study evaluated 1,124 patien

267 The Acute Renal Failure Trial Network study was a multicenter, pro

268 erbilirubinemia and/or Encephalopathy and/or Renal Failure trial.

269 Twenty-two patients with T1D and end-stage renal failure undergoing islet transplantation were comp

270 Patients with renal failure undergoing maintenance haemodialysis are a

271 ath, myocardial infarction, stroke, or acute renal failure up to the time of hospital discharge.

272 liver diseases, gastrointestinal hemorrhage, renal failure, urinary tract calculus, chronic ulcer of

273 ed mortality, heart failure hospitalization, renal failure, ventilation, and bleeding/transfusion wit

274 (range, 1-41) years in 77 patients, chronic renal failure was detected in 19 patients (25%): one req

275 ortality, heart failure hospitalization, and renal failure was highly concordant between physician ad

276 ricular heterotopias, echogenic kidneys, and renal failure was homozygous for p.Arg633Trp in CRB2.

277 Renal failure was induced in Sprague-Dawley rats by a hi

278 However, the effect on renal failure was not significant (0.95, 0.84-1.07).

279 In the latter patient, acute renal failure was not suspected to be related to everoli

280 toperative complications (eg, respiratory or renal failure) was assessed using c-statistic methodolog

281 Three main outcomes related to acute renal failure were analyzed: the need for renal replacem

282 mbolism of 4.90% (4.43-5.37), and those with renal failure were at higher risk of intracranial bleedi

283 ortality, heart failure hospitalization, and renal failure were consistent with clinician-triggered a

284 rparathyroidism, multiglandular disease, and renal failure were excluded.

285 outcomes other than stroke, retinopathy, and renal failure were lower in studies with greater baselin

286 critical care management for respiratory and renal failure were needed; 81.5% of these patients who r

287 ria, proteinuria >/=1 g/d, hypertension, and renal failure were observed in 97.4%, 84.8%, 85.3%, and

288 icemia, acute respiratory failure, and acute renal failure were the most common causes for readmissio

289 ure), and safety (serious adverse events and renal failure) were evaluated.

290 observed in vitamin D deficiency and chronic renal failure, where concentrations of the active vitami

291 cement therapy (CRRT) benefits patients with renal failure who are too hemodynamically unstable for i

292 myocardial infarction, stroke, or new-onset renal failure with dialysis by hospital discharge or by

293 myocardial infarction, stroke, or new-onset renal failure with dialysis, with less blood transfused.

294 hemolytic anemia, thrombocytopenia and acute renal failure with multiple organ involvement.

295 cantly later with comorbid heart failure and renal failure, with absence of fever or hypotension, and

296 diomyopathy, ischemic heart disease; chronic renal failure, with and without dialysis; hepatitis and

297 cisplatin at 2 mg/kg induced KIN that led to renal failure within 5 weeks in Fan1(-/-) mice but not i

298 phthisis, typically progressing to end-stage renal failure within the first two decades of life, thus

299 n policies prioritize kidneys to patients in renal failure within the first year following OLT.

300 sangial IgA1 deposits, is a leading cause of renal failure worldwide.